Form 4: Zenas BioPharma CEO Buys $1.6M in Company Stock

Zenas BioPharma's CEO, Leon O. Moulder, Jr., acquired 100,000 shares of common stock over three days in early January 2026, totaling approximately $1.6 million.

Summary

• Leon O. Moulder, Jr., the Chief Executive Officer and a Director of Zenas BioPharma, Inc. (ZBIO), reported open market purchases of the company's common stock.
• A total of 100,000 shares were acquired across three separate transactions on January 7, 8, and 9, 2026.
• The purchases were made at weighted average prices of $16.38, $16.30, and $16.55 per share, respectively.
• The total value of these transactions amounts to approximately $1,639,000.
• Following these transactions, Mr. Moulder's direct beneficial ownership increased to 366,155 shares.
• Mr. Moulder also has indirect beneficial ownership of 36,928 shares through the Leon O. Moulder, Jr. Revocable Trust and 1,672,039 shares through Tellus BioVentures LLC, where he is the Managing Member.

Sentiment

Score: 9

Explanation: The CEO's significant open market purchases demonstrate strong confidence in the company's valuation and future prospects, which is a highly positive signal for investors.

Positives

• The CEO's significant open market purchases of 100,000 shares demonstrate strong confidence in Zenas BioPharma's current valuation and future prospects.
• A substantial investment of approximately $1.6 million by a key executive often signals a positive internal outlook on the company's strategic direction and potential for growth.

Future Outlook

NA

Industry Context

Insider purchases by a CEO often signal strong internal confidence in a company's future, which can be particularly impactful in the biotechnology sector where success is heavily tied to pipeline development and regulatory approvals. Such actions can reassure investors about the company's trajectory.

Related Party Transactions

• Leon O. Moulder, Jr. is a Trustee of the Leon O. Moulder, Jr. Revocable Trust, which holds 36,928 shares of Zenas BioPharma Common Stock.
• Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC, which holds 1,672,039 shares of Zenas BioPharma Common Stock.

Stakeholder Impact

• Shareholders: May view the CEO's substantial purchases as a strong vote of confidence, potentially leading to increased investor interest and positive sentiment towards the stock.
• Employees: Could interpret the insider buying as a positive signal about the company's stability and future growth prospects, potentially boosting morale.

Key Dates

Recommendation

The Chief Executive Officer's substantial open market purchases of company stock, totaling approximately $1.6 million, signal strong conviction in Zenas BioPharma's future performance and valuation. This insider buying activity often precedes positive developments and suggests that management believes the stock is undervalued, making it a compelling 'buy' signal for investors.

Keywords

Zenas BioPharma, ZBIO, insider trading, stock purchase, CEO, Form 4, beneficial ownership, common stock, biopharma